UCSF Dermatology Grand Rounds - 3 April 2024

Wednesday, April 03 at 8:10 am - 10:15 am Add to Calendar 2024-04-03 15:10:00 2024-04-03 17:15:00 UCSF Dermatology Grand Rounds - 3 April 2024 GRAND ROUNDS AND PATIENT VIEWING Opportunities and Challenges in the Treatment of Human Papillomavirus InfectionCarrie Kovarik, MD, Professor, Dermatology, Dermatopathology, Infectious Diseases, University of Pennsylvania, Philadelphia, PAObjectives:1. Determine treatment options for challenging cases of Human Papillomavirus (HPV) on the skin and mucous membranes 2. Understand when to consider malignancy in cases of HPV and how to work with other specialties to optimize treatment Speaker Disclosures: Carrie Kovarik, MD has stated that she has no financial relationships to disclose. Moderator Disclosures: Anna Haemel, MD has disclosed that she is an advisor or reviewer for CSL Behring, a consultant for Guidepoint LLC and receives a research grant from Priovant. Planner Disclosures: Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01). Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose. 1600 Divisadero Street Herbst Hall Auditorium San Francisco, CA 94115 United States View on Map Department Of Dermatology Laura.Harrison@ucsf.edu America/Los_Angeles public

1600 Divisadero Street
Herbst Hall Auditorium
San Francisco, CA 94115
United States

View on Map

GRAND ROUNDS AND PATIENT VIEWING

Opportunities and Challenges in the Treatment of Human Papillomavirus Infection
Carrie Kovarik, MD, Professor, Dermatology, Dermatopathology, Infectious Diseases, University of Pennsylvania, Philadelphia, PA
Objectives:
1. Determine treatment options for challenging cases of Human Papillomavirus (HPV) on the skin and mucous membranes
2. Understand when to consider malignancy in cases of HPV and how to work with other specialties to optimize treatment

Speaker Disclosures: Carrie Kovarik, MD has stated that she has no financial relationships to disclose.

Moderator Disclosures: Anna Haemel, MD has disclosed that she is an advisor or reviewer for CSL Behring, a consultant for Guidepoint LLC and receives a research grant from Priovant.

Planner Disclosures:
Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials
Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).
Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.